Fig 1.
Estimated subtype-specific cumulative incidence of relapse over time according to treatment group (CMF [cyclophosphamide, methotrexate, and fluorouracil] chemotherapy v no CMF chemotherapy) for patients with (A) triple-negative, (B) human epidermal growth factor receptor 2 (HER2) –positive, endocrine receptor–absent, or (C) endocrine receptor–present tumors.
